Drug intelligence / Profile preview

donafenib + tislelizumab

Development stage: Unknown
Lead developer: Suzhou Zelgen Biopharmaceuticals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

A combination therapy consisting of donafenib, an oral multikinase inhibitor targeting VEGFR, PDGFR, and Raf kinases, and tislelizumab, a humanized IgG4 monoclonal antibody targeting PD-1. This combination aims to suppress tumor cell proliferation and angiogenesis while enhancing immune response against tumor cells. The combination is being investigated in clinical trials for hepatocellular carcinoma (HCC) and biliary tract cancer (BTC).

Targets

PDGFRB (Platelet-derived growth factor receptor beta)PDCD1 (Programmed cell death protein 1 receptor)BRAF V600EVEGFR4 (Vascular endothelial growth factor Receptor-3)RAF1 (c-Raf-1 (Y340D/Y341D))VEGFR2 (Vascular endothelial growth factor receptor 2)

Beyond the preview

Go deeper on donafenib + tislelizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on donafenib + tislelizumab.

Explore the full profile